Drug Profile
RG 8803
Latest Information Update: 11 Nov 2003
Price :
$50
*
At a glance
- Originator Repligen
- Class Antineoplastics; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor inhibitors; Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Diabetic retinopathy
Most Recent Events
- 11 Nov 2003 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 11 Nov 2003 Discontinued - Preclinical for Diabetic retinopathy in USA (unspecified route)
- 12 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)